The existence of COPD and heart failure in elderly population adds additional morbidity and mortality risk than if those with only one of the two comorbidities. The aim of the current metaanalysis was to explore the effect of COPD on heart failure patient in terms of all-cause mortality, cardiac mortality and recurrent heart failure hospitalization.
Introduction
The co-occurrence of Heart Failure (HF) and Chronic Obstructive Pulmonary Disease (COPD) that share common clinical presentation and risk factors is common in the elderly population, such overlap makes the diagnosis of COPD in HF and vice versa challenging [1, 2] .
The existence of these clinical syndromes in elderly population adds additional morbidity and mortality risk than if those with only one of these diseases [3] . Furthermore, it will add dilemma to recognition of each when these disorders exist and leads to over diagnosis of heart failure in COPD patient or under diagnosis of COPD in heart failure patients [4] . Treatment interaction, the more complex issue is that the treatment of one may adversely affect the other [5] , as bronchodilator may cause tachycardia and may precipitate heart failure furthermore beta blockers and diuretics may adversely affect COPD.
The above 2 clinical presentation has not analyzed systematically, with the presence of only observational studies that supply both cardiologist and internist with inconsistent information. We choose to systematically analyze the available research article, so we can reach fi nal conclusion about the morbidity and mortality interaction between these conditions when heart failure patient with COPD presented with acute exacerbation.
The aim of the current meta-analysis was to explore the effect of COPD on heart failure patient in term of short-and long-term all-cause mortality and cardiac mortality and the effect of COPD on recurrent heart failure hospitalization. studies. References cited in the studies were reviewed for additional information. The fl ow diagram shown in Figure 1 , the search strategy yields 15 observational studies that met the study criteria.
Methods

Search strategy & data collection
Criteria for study selection and qualitative assessment
The inclusion and exclusion criteria for the studies in the current meta-analysis are shown in Figure 2 . Data regarding publication status, study design, patient-related characteristics, treatment regimens, outcome methods and results was extracted according to the standard protocol independently by 2 individual researchers. Any confl icts or incongruities were resolved by mutual agreement.
Clinical end points studied
The clinical endpoints that were analyzed in this metaanalysis are short-and long-term all-cause mortality, early and late cardiac mortality in all COPD patient and in subgroups as per COPD GOLD stages, recurrent heart failure hospitalization and the effect of B blocker treatment on all-cause mortality.
Statistical analysis
Review manager 5.3 (The Nordic Cochrane Centre, The
Cochran Collaboration, Copenhagen, Denmark) was used for the analysis. The total standardized mean difference (SMD), with 95% confi dence interval (CI), was estimated for fi xed and random effects models to present "pooled effect" for continuous outcomes (mean ± standard deviation or median ± interquartile range) & categorical outcomes (Odds risk OR). Statistical heterogeneity among studies was assessed with Cochran's Q test and the I2 statistic. The studies were considered statistical heterogeneous if p <0.05 and I 2 ≥ 50% [6, 7] . A random effect model was used for analysis to determine the heterogeneity, and fi xed effect model was used in case of homogeneity. Statistical signifi cance value was set at 0.05. Processing of the data and reporting of results were performed according to accepted principles of systemic review and meta-analysis. In order to assess potential publication bias, or "small-study effect", we used the funnel plot, which provides a good visual evaluation of sampling bias.
Results
A total of 15 observational studies [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] , were identifi ed, the baseline clinical characteristics of the patients included are shown in Table 1 , Males were the predominant gender in these studies with the mean age shown being above 65 years of age with similar rate of CAD hypertension and dyslipidemia.
Patients with COPD and heart failure have higher short term (in-hospital, 1-3 months) (P=0.009, 0.0006 respectively, and long-term mortality (1 year, 2-5 years) (P=0.00001 for both) with moderate heterogeneity between the included studies) Figure 3 .
The short-term cardiac mortality appears to be nonsignifi cantly (P=0.07) higher in COPD patients while the longterm cardiac mortality appears to be signifi cantly higher (P=0.02) in COPD patient with heart failure with moderate heterogeneity between the included studies The heterogeneity of all the variable analyzed is shown in Funnel plots in Figure 6 .
Patient with advanced stage [11, 13, 19] , of COPD i.e. GOLD stage II-IV when compared to GOLD 0-I and non-COPD had higher long-term all-cause mortality (P<0.0001) [11, 19] , but not long-term cardiac mortality (P=NS). Figure 7 A,B.
Beta blockers treatments appear to decrease all-cause mortality [8, 10, 11] , in COPD with heart failure as it does with non-COPD with heart failure (P <0.0001) Figure 7 C.
The multivariate analysis of the all-cause mortality predictors was shown in Table 2 . The age, diabetes, COPD stage, low ejection fraction, and impaired renal function were the most frequent predictors in the included studies.
Discussion
Heart failure and COPD as combined comorbidities presents a great diagnostics and therapeutic challenges, because both conditions share features such as; presentation in advanced age, common symptoms of dyspnea and smoking as a risk factor, in addition to that, treatment of one condition may affects the other [1] . Unfortunately, this issue has not been studied systematically in randomized stream and even forgotten in major clinical trials. To the best of our knowledge this the fi rst meta-analysis that explored the impact of COPD in heart failure patient. The absence of randomized trial makes the fi nal result biased in many aspects. As we can see from the current analysis, few conclusions have been withdrawn:
First: The presence of COPD adds an increased risk of both short and long term all-cause and long-term cardiac mortality in period of the follow up of the included studies which appear to be satisfactory in most of the studies that reach up to 5 years.
Second: Heart failure exacerbation on the background of COPD may be explained by many mechanisms; the low-grade infl ammation, underuse of -blockers, and adverse CV effects of bronchodilators [14, 15] . The increased hospitalization rates in patients with HF and COPD may also be related to improvement in HF prognosis with contemporary therapies i.e. increase heart failure population. Alternatively, the improved survival of patients with HF and COPD, there is a larger population at risk for hospitalization.
Third: The severity of COPD appears to be directly proportional to the heart failure all-cause mortality and cardiac mortality and it appear that heart failure patient with advanced COPD i.e. GOLD stage ≥ II die from non-cardiac causes that related to associated comorbidities like diabetes and renal failure and advanced age as shown the mortality predictors in Table 2 , though the mortality predictors were assessed only in few studies.
Fourth: Treatment of HF as per heart failure guidelines, necessitate the addition of beta blockers even in COPD patients, because there is no evidence that HF should be treated differently in patients with this comorbidity. B-Blockers are strongly recommended in all patients with systolic HF, including those with coexistent COPD [23-25], with cardioselective b-blockers as the default [26, 27] . The result from the current analysis showed that treatment with B blocker had mortality benefi t though this issue has been assessed in 3 studies [8, 10, 11] , only, but still it gives the preliminary idea that beta blockers are safe in the patients subset, though we are unable to analyze the beta blocker selectivity as this issue has not been investigated in the included studies and despite concerns regarding  blockers in patients with HF with COPD, there was no evidence that -blocker selectivity was associated with differences in outcomes for patients with HF with COPD versus those without as in OPTIMIZE-HF registry sub-analysis [28] . The available evidence suggests that COPD patients treated with cardio selective beta-blockers has no signifi cant short-term impact on airway function or COPD exacerbations.
However, the trials were small and of short duration. Given their substantiated benefi t in conditions such as heart failure, 
Fifth:
The mortality predictors in this patient's population are variable but there are common predictors as shown in Table 1 , these predictors appear to be the combination of mortality risk factors of COPD and HF, such as age, diabetes, chronic kidney disease, low ejection fraction, in addition to well-known other factors like liver disease, low systolic blood pressure, lower serum sodium, lower admission weight, and depression. The use of statins and beta-blockers at discharge was associated with signifi cantly decreased mortality as shown in retrospective analysis of OPTIMIZE-HF registry in patient without COPD [29] .
Strength and limitations
The strength of this research is that it is the fi rst metaanalysis done in this fi eld of heart failure patients with COPD who presented acutely or chronically. The current metaanalysis result was extracted from observational studies most of which are retrospective analysis of major heart failure registries that can result in publication bias. In addition, the defi nition and staging of COPD was not available in many studies and that patient were considered to have COPD as per medical record and no spirometry done in these studies (only one prospective study included), the low number of patients included explore the need for large study that can achieve statistical power. The conclusion regarding B blockers in heat failure patient with COPD need to be interpreted carefully as this include relatively small number of patients from few retrospective studies though one of which was retrospective analysis of major heart failure registry, again necessitate the need for a large randomized controlled trial in this fi eld.
Conclusion
Heart failure patient with COPD appear to have more frequent heart failure hospitalization, higher long-term cardiac mortality, short-and long-term all-cause mortality and this more apparent in advanced stages of COPD refl ect the synergistic effect of both comorbidities. Beta blockers use appear to be safe as it decreases mortality in these patients.
